A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects.
Phase of Trial: Phase III
Latest Information Update: 12 May 2016
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms BIRTH
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2015 Interim results (SVR 12, n=257 ) presented at the IDWeek 2015
- 05 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.